TEM vs GEHC
diagnostics · organic revenue
| TEM diagnostics Healthcare | GEHC organic revenue Healthcare | |
|---|---|---|
| Market | ||
| Price | $81.52 +3.87% | $79.80 +0.31% |
| Market cap | $13.2B | $34.6B |
| P/E (TTM) | — | 17.4 |
| Dividend yield | — | 0.16% |
| 52-week range | $40.77 – $91.83 | $58.75 – $89.77 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Tempus Grew Revenue 23%, But A $42.8 Million Securities Gain Helped The Loss Nov 3, 2026 | GE HealthCare Expanded Margin 180 Basis Points, With A $55M Tariff Refund Nov 3, 2026 |
| Latest earnings | ||
| Reported | — | — |
| Revenue | — | — |
| EPS | — | — |
| Guidance | — | — |
| Revenue growth, last 4 reports | — | — |
| Topics | ||
| Main topics | ||
| Company page | Company page | |
Shared topics: Margins
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.